Kaken Pharmaceutical Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Hiroyuki Horiuchi
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4.6yrs |
| CEO ownership | 0.02% |
| Management average tenure | no data |
| Board average tenure | 3.1yrs |
Recent management updates
Recent updates
Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00
Dec 20
Kaken Pharmaceutical (TSE:4521) Will Pay A Dividend Of ¥75.00
Dec 02Estimating The Intrinsic Value Of Kaken Pharmaceutical Co., Ltd. (TSE:4521)
Aug 13Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00
Jul 26Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00
Jul 11Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00
Mar 04CEO
Hiroyuki Horiuchi (62 yo)
4.6yrs
Tenure
Mr. Hiroyuki Horiuchi serves as Director of Kaken Pharmaceutical Co. Ltd. since June 2016 and has been its President since June 2020. He is the Chairman of Kaken Pharmaceutical Co. Ltd.He was Chief Office...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 8.6yrs | no data | 0.020% ¥ 34.7m | |
| MD & Director | 3.6yrs | no data | 0.0084% ¥ 14.4m | |
| Head of Research and Development & Director | 1.6yrs | no data | 0.0063% ¥ 10.8m | |
| Independent Outside Director | 4.6yrs | no data | 0.0013% ¥ 2.3m | |
| Independent Outside Director | 3.6yrs | no data | 0.00026% ¥ 444.4k | |
| Outside Audit & Supervisory Board Member | 1.6yrs | no data | 0.00026% ¥ 444.4k | |
| Auditor | 1.6yrs | no data | 0.015% ¥ 26.2m | |
| Director | 4.6yrs | no data | 0.014% ¥ 24.4m | |
| Director | less than a year | no data | no data | |
| Outside Audit & Supervisory Board Member | 3.6yrs | no data | 0.0011% ¥ 1.8m | |
| Standing Audit & Supervisory Board Member | 2.6yrs | no data | 0.0050% ¥ 8.6m | |
| Independent Outside Director | less than a year | no data | no data |
3.1yrs
Average Tenure
61.5yo
Average Age
Experienced Board: 4521's board of directors are considered experienced (3.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 01:44 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kaken Pharmaceutical Co., Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |
| Junya Yamazaki | Jefferies LLC |
| Toshiyuki Iwata | Mizuho Securities Co., Ltd. |